Focused Ultrasound For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Focused Ultrasound For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Focused Ultrasound (FUS) is a non-invasive therapeutic technology that uses acoustic energy to precisely target brain regions for treatment of neurodegenerative diseases. It offers a unique combination of thermal ablation, [blood-brain barrier](/entities/blood-brain-barrier) (BBB) opening, and neuromodulation without surgical intervention. [@focused2020]
Technology Platforms
High-Intensity Focused Ultrasound (HIFU)
Mechanism: Thermal ablation through focused acoustic energy
Applications: Thalamotomy for tremor, target ablation in movement disorders
FDA Approved: Essential tremor, Parkinson's disease tremor
[Aβ](/proteins/amyloid-beta) Reduction: Direct mechanical disruption of plaques
Neuroinflammation: Modulation of microglial activation
Biomarker Release: Collects AD biomarkers via BBB opening
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS): Motor [cortex](/brain-regions/cortex) application
Multiple Sclerosis: Myelin repair enhancement
Brain Tumors: Drug delivery enhancement
Mechanism of Action
Thermal Effects (HIFU)
Protein denaturation at temperatures >55°C
Coagulation necrosis of targeted tissue
Precise lesioning with sub-millimeter accuracy
BBB Opening (FUS-BBBO)
Transient opening of endothelial tight junctions
Enhanced delivery of therapeutic agents
Duration: 4-6 hours typically
Repeat treatments possible
Neuromodulation (LIFU)
Neuronal excitation or inhibition
Modulation of neural circuits
Non-invasive alternative to DBS
Clinical Evidence
Essential Tremor
Phase III Trial: 76% tremor reduction at 1 year
FDA Approval: 2016 for essential tremor
Durability: Sustained benefit through 5 years
Parkinson's Disease Tremor
Phase III Trial: Significant OFF-medication tremor reduction
Motor Complications: Improved quality of life
Comparison: Non-inferior to DBS in selected patients
Alzheimer's Disease (FUS-BBBO)
Phase I Trial: Safe BBB opening, reduced [Aβ](/proteins/amyloid-beta) plaques
Phase II Trial: Improved cognition with anti-amyloid antibodies
Ongoing: Multi-center trials
Treatment Procedure
Pre-Treatment
MRI for targeting
Skull CT for bone correction
Patient screening for eligibility
Anesthesia or sedation as needed
During Treatment
Stereotactic frame placement
Real-time MRI guidance
Sonications (30-60 seconds each)
Temperature monitoring
Clinical monitoring
Post-Treatment
MRI to confirm lesion/treatment
Neurological assessment
Follow-up imaging
Rehabilitation if needed
Combination Therapies
Safety Profile
Common Adverse Events
Headache (transient)
Dizziness
Mild confusion
Scalp discomfort
Rare Complications
Intracranial hemorrhage
Thermal injury to off-target tissue
Permanent neurological deficits (<1%)
Edema at treatment site
Contraindications
Metallic implants in treatment path
Uncontrolled hypertension
Coagulopathy
Pregnancy
Background
The study of Focused Ultrasound For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions